Topical XXXX in the treatment of @entity3169 .

@entity1 @entity1138 @entity1139 @entity3169 @entity320
PURPOSE: To assess the clinical efficacy of topical @entity1138 ( @entity1139 ) 0.04% for the treatment of @entity1 with @entity3169 . Clinical efficacy was evaluated on the basis of reduction in lesion size and degree of pigmentation and histologic study. METHODS: Two @entity1 , one with primary acquired @entity3169 with atypia and another with @entity320 , were treated with topical @entity1139 0.04%. Before treatment, a biopsy was performed that confirmed the diagnosis and the absence of atypical melanocytes beyond the basal layer. In both @entity1 , @entity1139 was administered with sponges, while one @entity1 additionally received @entity1139 0.04% drops. Each treatment cycle lasted 14 days, with repetition after 3 months when necessary. Follow-up was weekly, then monthly, and then every 6 months up to 3 years. RESULTS: Treatment with topical @entity1139 0.04% not only reduced the size and degree of pigmentation clinical lesions in both @entity1 but also eradicated atypical conjunctival melanocytes as observed in histologic studies. In the @entity1 with primary acquired @entity3169 , adjunct cryotherapy was required, along with various cycles of @entity1139 , to reduce the pigmented areas of skin of the internal canthus and caruncle. In the second case, only @entity1139 was used. No severe adverse reactions to the treatment were observed. After 3 years of follow-up, no clinical relapse has been detected. CONCLUSION: Topical @entity1139 0.04% is an option worth considering for the treatment of @entity3169 , particularly as an adjunct to other forms of treatment.
